The Non-Small Cell Lung Carcinoma drugs in development market research report provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Non-Small Cell Lung Carcinoma. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Non-Small Cell Lung Carcinoma and features dormant and discontinued products.
GlobalData tracks 89 drugs in development for Non-Small Cell Lung Carcinoma by 77 companies/universities/institutes. The top development phase for Non-Small Cell Lung Carcinoma is phase ii with 31 drugs in that stage. The Non-Small Cell Lung Carcinoma pipeline has 80 drugs in development by companies and nine by universities/ institutes. Some of the companies in the Non-Small Cell Lung Carcinoma pipeline products market are: Xiangxue Life Sciences, AstraZeneca and U.S. National Institutes of Health.
The key targets in the Non-Small Cell Lung Carcinoma pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274), and Serine/Threonine Protein Kinase mTOR (FK506 Binding Protein 12 Rapamycin Complex Associated Protein 1 or FKBP12 Rapamycin Complex Associated Protein or Mammalian Target Of Rapamycin or Mechanistic Target Of Rapamycin or Rapamycin And FKBP12 Target 1 or Rapamycin Target Protein 1 or MTOR or EC 2.7.11.1).
The key mechanisms of action in the Non-Small Cell Lung Carcinoma pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with eight drugs in Phase III. The Non-Small Cell Lung Carcinoma pipeline products include 13 routes of administration with the top ROA being Intravenous and 13 key molecule types in the Non-Small Cell Lung Carcinoma pipeline products market including Small Molecule, and Monoclonal Antibody.
Non-Small Cell Lung Carcinoma overview
Non-small cell lung carcinoma (NSCLC) is the most common type of lung cancer. “Non-small cell” refers to the way cancer cells look under a microscope. If the cells look small, the cancer is referred to as small cell lung cancer (SCLC). According to the American Cancer Society, about 80 to 85 percentTrusted Source of all lung carcinomas fall into the non-small cell category. NSCLC doesn’t tend to spread as fast as SCLC and has a better survival rate.
For a complete picture of Non-Small Cell Lung Carcinoma’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
